Source-grounded facts extracted from Jazz Pharmaceuticals plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Anne O'Riordan departed as Director at Jazz Pharmaceuticals plc.
“On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.”
Jazz Pharmaceuticals plc reported first quarter of 2026 (1Q26) results: revenue $1.1 billion, EPS $4.43 / $6.34. Guidance reaffirmed.
“filing. --- EX-99.1 (EX-99.1) --- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ®”
Catherine Sohn departed as Director at Jazz Pharmaceuticals plc.
“On May 31, 2024, Catherine Sohn, Pharm.D. notified the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), that she is retiring and will not stand for re-election to the Board, when her term expires, at the Company’s 2024 annual general meeting of shareholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.